BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Coeptis Therapeutics Holdings, Inc. (Nasdaq – COEP), Pacific Premier Bancorp, Inc. (Nasdaq - PPBI)
Investigations Announced: Brodsky & Smith is investigating potential breaches of fiduciary duties by the boards of Regulus Therapeutics, Kronos Bio, Coeptis Therapeutics, and Pacific Premier Bancorp regarding their acquisition agreements, questioning whether shareholders are receiving fair value for their shares.
Acquisition Details: Each company mentioned has entered into merger agreements with various firms, with specific terms including cash payments and contingent value rights, raising concerns about the fairness of the processes followed by their respective boards.
Trade with 70% Backtested Accuracy
Analyst Views on COEP
About COEP
About the author
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
Coeptis Therapeutics Secures SEC Approval for Merger with Z Squared Inc.
- Merger Progress: Coeptis Therapeutics announced that its registration statement for the merger with Z Squared has been approved by the SEC, marking a significant step forward that is expected to enhance the company's market competitiveness.
- Shareholder Meeting Arrangement: The company will hold a special shareholder meeting on January 30, 2026, to discuss the merger, with the proxy statement and prospectus being mailed to shareholders on January 7, ensuring transparency and shareholder engagement.
- Listing Application Update: The combined company has applied for a Nasdaq listing, and while approval is pending, this move indicates the company's proactive approach to future capital markets, which, if successful, will enhance its market recognition.
- Technology and Business Integration: By merging with Z Squared, Coeptis aims to integrate its biopharmaceutical technologies with cryptocurrency mining operations, driving innovation and diversification to bolster long-term growth potential.
SHAREHOLDER RIGHTS NOTICE: Halper Sadeh LLC Probes BFIN, COEP, ARIS, CIO for Shareholder Interests
Investigation of Companies: Halper Sadeh LLC is investigating BankFinancial Corporation, Coeptis Therapeutics Holdings, Aris Water Solutions, and City Office REIT for potential violations of federal securities laws and breaches of fiduciary duties related to their recent transactions.
Legal Rights for Shareholders: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options, with the firm offering services on a contingent fee basis, meaning no upfront costs for legal fees.
URGENT: M&A Class Action Firm Ongoing Investigation into the Merger Involving BFIN, ARIS, CIO, and COEP
Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders.
Ongoing Investigations: The firm is currently investigating several companies, including BankFinancial Corporation, Aris Water Solutions, City Office REIT, and Coeptis Therapeutics, regarding their proposed mergers and sales, with shareholder votes scheduled for October 2025.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CYBR, UNP, COEP on Behalf of Shareholders
Investigation Announcement: Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to several companies, including CyberArk Software Ltd., Union Pacific Corporation, and Coeptis Therapeutics Holdings, Inc.
CyberArk Software Details: The investigation focuses on CyberArk's sale to Palo Alto Networks, which involves a cash payment and shares of Palo Alto common stock for each CyberArk share.
Union Pacific and Coeptis Mergers: The firm is also looking into Union Pacific's merger with Norfolk Southern and Coeptis' merger with Z Squared, assessing shareholder rights and options.
Legal Support Offered: Halper Sadeh LLC offers legal assistance on a contingent fee basis, encouraging shareholders to contact them for free consultations regarding their legal rights and potential actions.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, COEP, AVDX on Behalf of Shareholders
Investigation of Companies: Halper Sadeh LLC is investigating Sage Therapeutics, Coeptis Therapeutics, and AvidXchange Holdings for potential violations of federal securities laws related to their recent transactions, including sales and mergers.
Legal Support for Shareholders: The firm offers free consultations to shareholders regarding their legal rights and options, emphasizing that they operate on a contingency fee basis, meaning no upfront costs for legal fees.
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
Coeptis Therapeutics Secures SEC Approval for Merger with Z Squared Inc.
- Merger Progress: Coeptis Therapeutics announced that its registration statement for the merger with Z Squared has been approved by the SEC, marking a significant step forward that is expected to enhance the company's market competitiveness.
- Shareholder Meeting Arrangement: The company will hold a special shareholder meeting on January 30, 2026, to discuss the merger, with the proxy statement and prospectus being mailed to shareholders on January 7, ensuring transparency and shareholder engagement.
- Listing Application Update: The combined company has applied for a Nasdaq listing, and while approval is pending, this move indicates the company's proactive approach to future capital markets, which, if successful, will enhance its market recognition.
- Technology and Business Integration: By merging with Z Squared, Coeptis aims to integrate its biopharmaceutical technologies with cryptocurrency mining operations, driving innovation and diversification to bolster long-term growth potential.
SHAREHOLDER RIGHTS NOTICE: Halper Sadeh LLC Probes BFIN, COEP, ARIS, CIO for Shareholder Interests
Investigation of Companies: Halper Sadeh LLC is investigating BankFinancial Corporation, Coeptis Therapeutics Holdings, Aris Water Solutions, and City Office REIT for potential violations of federal securities laws and breaches of fiduciary duties related to their recent transactions.
Legal Rights for Shareholders: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options, with the firm offering services on a contingent fee basis, meaning no upfront costs for legal fees.
URGENT: M&A Class Action Firm Ongoing Investigation into the Merger Involving BFIN, ARIS, CIO, and COEP
Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders.
Ongoing Investigations: The firm is currently investigating several companies, including BankFinancial Corporation, Aris Water Solutions, City Office REIT, and Coeptis Therapeutics, regarding their proposed mergers and sales, with shareholder votes scheduled for October 2025.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CYBR, UNP, COEP on Behalf of Shareholders
Investigation Announcement: Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to several companies, including CyberArk Software Ltd., Union Pacific Corporation, and Coeptis Therapeutics Holdings, Inc.
CyberArk Software Details: The investigation focuses on CyberArk's sale to Palo Alto Networks, which involves a cash payment and shares of Palo Alto common stock for each CyberArk share.
Union Pacific and Coeptis Mergers: The firm is also looking into Union Pacific's merger with Norfolk Southern and Coeptis' merger with Z Squared, assessing shareholder rights and options.
Legal Support Offered: Halper Sadeh LLC offers legal assistance on a contingent fee basis, encouraging shareholders to contact them for free consultations regarding their legal rights and potential actions.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, COEP, AVDX on Behalf of Shareholders
Investigation of Companies: Halper Sadeh LLC is investigating Sage Therapeutics, Coeptis Therapeutics, and AvidXchange Holdings for potential violations of federal securities laws related to their recent transactions, including sales and mergers.
Legal Support for Shareholders: The firm offers free consultations to shareholders regarding their legal rights and options, emphasizing that they operate on a contingency fee basis, meaning no upfront costs for legal fees.
